Information Provided By:
Fly News Breaks for January 8, 2018
FLXN
Jan 8, 2018 | 11:57 EDT
Wells Fargo analyst David Maris said he remains excited about Zilretta and its longer-term growth potential and he is encouraged by initial data from its Phase 3B trial evaluating repeat administration in patients with OA of the knee. Maris, who estimates Zilretta sales of approximately $196M in 2019, keeps an Outperform rating on Flexion shares.
News For FLXN From the Last 2 Days
There are no results for your query FLXN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.